Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) represent severe conditions with high mortality rates, often stemming from overwhelming infections or inflammatory responses. The critical need for effective treatments that can mitigate lung damage and inflammation has driven research into various therapeutic agents, including natural compounds.

Luteolin, a well-studied flavonoid, has shown considerable promise in preclinical models of ALI and ARDS. Its pharmacological activities are diverse, with particular emphasis on its potent anti-inflammatory and antioxidant effects, which are central to managing the pathophysiology of these conditions. In models of sepsis-induced ALI, luteolin has been observed to reduce inflammatory mediators such as TNF-α, IL-6, and IL-1β by modulating key signaling pathways like NF-κB and MAPK. This action helps to dampen the excessive inflammatory cascade that damages lung tissue.

Furthermore, luteolin's antioxidant capacity is vital in combating the oxidative stress that exacerbates ALI/ARDS. By scavenging reactive oxygen species (ROS) and enhancing the activity of endogenous antioxidant enzymes, luteolin helps protect lung cells from damage. Studies also suggest that luteolin can positively influence alveolar sodium channels (ENaC), which are crucial for clearing excess fluid from the lungs – a hallmark of pulmonary edema in ARDS.

For healthcare innovators and pharmaceutical companies seeking to leverage natural compounds for critical care applications, sourcing high-quality luteolin is essential. NINGBO INNO PHARMCHEM CO.,LTD. is a dedicated manufacturer and supplier of pharmaceutical intermediates, offering pure luteolin (CAS 491-70-3) with a minimum purity of 99.0% (HPLC). Our commitment to quality ensures that you receive reliable materials for your research and development efforts aimed at treating ALI/ARDS. We provide competitive pricing for bulk purchases, making us an accessible luteolin supplier in China.

The potential for luteolin to serve as a therapeutic agent in ALI/ARDS is supported by a growing body of scientific evidence. Its ability to target multiple pathways involved in lung inflammation and injury makes it a compound of significant interest. If your organization is looking to purchase luteolin for pharmaceutical development in the critical care sector, consider the quality and reliability offered by NINGBO INNO PHARMCHEM CO.,LTD. We are equipped to meet your demands for this vital natural compound.